Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis

Home » Archive by Tags

Articles tagged with: HEB

Hemispherx’s Vaccine Enhancer Making Waves in Japan (AMEX:HEB)
09/29/2009 – 4:38 am PDT | Comments Off

Hemispherx Biopharma, Inc. (AMEX:HEB) is in the news after it was announced that Dr. Hasegawa the director of the Japanese National Institute of Infectious Diseases presented data on the lead compounds of Ampligen (R) (Poly …

Justin Hall Agrees - FDA Calendar ‘Should Be Free’ (CTIC, HEB, VNDA, DSCO)
07/24/2009 – 6:00 am PDT | Comments Off

Justin Hall a blogger from SeekingAlpha says the FDA Calendar “should be free”in a recent blog entry.
After reading this I decided to check out Justin profile, since I have never heard of him, and I …

Why Does This Stock Continue To Drop After Great News? (ARDM, HEB, BDSI)
07/24/2009 – 6:00 am PDT | Comments Off

I find it odd thatAradigm Corporation(OTC:ARDM) stock price dropped the day after Zogenix, Inc. was granted approval of the Sumavel™ DosePro. ARDM gets a $4 Million milestone payment upon first commercial sale and royalty payments …

FDA’s Target Date For Aradigm Corporation (ARDM, HEB, DSCO, LLY, BDSI)
07/15/2009 – 6:00 am PDT | Comments Off

Aradigm Corporation (ARDM) is pending a FDA decision on their drug Liposomal Ciprofloxacin. Lets see if the FDA meets their target date. The FDA has recently misses some important target dates with Hemispherx BioPharma, Inc (Public, AMEX:HEB), Discovery …

Hemispherix Trading Halted? (DNDN, CTIC, PFE, HEB)
07/07/2009 – 6:00 am PDT | Comments Off

Reading some of the posts on the Yahoo message boards I see a lot of people talking about Hemispherix Biopharma (AMEX:HEB)trading is now halted. Obviously this is not true since the stock is not on the …

Will Hemispherx Biopharma Make The Cut? (HEB)
07/06/2009 – 6:00 am PDT | Comments Off

It has been over a month since the FDA last informed Hemispherx Biopharma (AMEX:HEB) “it may require up to 1-2 additional weeks” to make its decision on HEB’s drug Ampligen, a treatment for Chronic Fatigue …